Regulatory 2024-07-10 | Ascelia Pharma Carries Out a Rights Issue of Units of Approximately SEK 105 Million to Fully Finance the NDA Submission for Orviglance® PDF Report Presentation Webcast
Regulatory 2024-05-16 | Quarterly Report Q1: Primary Endpoint Met with Strong Headline Results in Orviglance Phase 3 Study PDF Report Presentation Webcast
Regulatory 2024-05-06 | Bulletin from the Annual General Meeting in Ascelia Pharma AB on 6 May 2024 PDF Report Presentation Webcast
Regulatory 2024-05-02 | Ascelia Pharma Successfully Meets Primary Endpoint with Strong Headline Results in Orviglance Phase 3 Study PDF Report Presentation Webcast
Regulatory 2024-04-08 | Annual Report 2023: Solid Progress with Orviglance Phase 3 Patient Recruitment Completed and Headline Results Expected by May 2024 PDF Report Presentation Webcast
Regulatory 2024-03-27 | Notice of Annual General Meeting in Ascelia Pharma AB PDF Report Presentation Webcast
Regulatory 2024-02-09 | Q4 and Full Year Report 2023: Strengthened Financial Position Ahead of SPARKLE Phase 3 Study Headline Results in May PDF Report Presentation Webcast
Regulatory 2024-02-04 | Ascelia Pharma Secures Financing of up to SEK 35 Million PDF Report Presentation Webcast
Regulatory 2024-01-24 | Nomination Committee Appointed for AGM 2024 in Ascelia Pharma AB PDF Report Presentation Webcast
Regulatory 2023-11-30 | Change in Number of Shares and Votes in Ascelia Pharma AB PDF Report Presentation Webcast
Regulatory 2023-11-13 | Bulletin from the Extraordinary General Meeting in Ascelia Pharma AB on 13 November 2023 PDF Report Presentation Webcast
Regulatory 2023-11-09 | Ascelia Pharma resolves on conversion of series C shares into ordinary shares for delivery to participants in incentive program PDF Report Presentation Webcast
Regulatory 2023-11-08 | QUARTERLY REPORT Q3 2023: Re-evaluation of SPARKLE Phase 3 Study Images Progresses According to Plan PDF Report Presentation Webcast
Regulatory 2023-10-19 | NOTICE OF EXTRAORDINARY GENERAL MEETING IN ASCELIA PHARMA AB PDF Report Presentation Webcast
Regulatory 2023-08-31 | Ascelia Pharma significantly reduces organization to reach SPARKLE headline results PDF Report Presentation Webcast
Regulatory 2023-08-18 | Half-Year report 2023: Re-evaluation required after intra-reader inconsistency in scoring of images from phase 3 study SPARKLE PDF Report Presentation Webcast
Regulatory 2023-08-07 | Re-Evaluation Required After Intra-Reader Inconsistency in Scoring of Images from Phase 3 Study SPARKLE PDF Report Presentation Webcast
Regulatory 2023-06-16 | Ascelia Pharma presented Orviglance Hepatic Impairment Data and hosted a Q&A with liver imaging experts at the 2023 ESGAR Annual Meeting PDF Report Presentation Webcast
